Recent studies have centered on the overlap of GLP|GIP|glucagon receptor agonist therapies and DA signaling. While GIP agonists are increasingly employed for managing type 2 diabetes, their potential impacts on reward https://aoifetefx333848.blogerus.com/63725681/emerging-glp-agonists-and-dopaminergic-influence-a-comparative-copyrightination